| Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS … E Van Cutsem, CH Köhne, I Láng, G Folprecht, MP Nowacki, S Cascinu, ... Journal of Clinical Oncology 29 (15), 2011-2019, 2011 | 2318 | 2011 |
| Bioresorbable airway splint created with a three-dimensional printer DA Zopf, SJ Hollister, ME Nelson, RG Ohye, GE Green New England Journal of Medicine 368 (21), 2043-2045, 2013 | 713 | 2013 |
| Addressing the challenges of pancreatic cancer: future directions for improving outcomes M Hidalgo, S Cascinu, J Kleeff, R Labianca, JM Löhr, J Neoptolemos, ... Pancreatology 15 (1), 8-18, 2015 | 598 | 2015 |
| Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: A meta-analysis of published randomised trials: A study of the GISCAD (Gruppo Italiano per lo … E Mari, I Floriani, A Tinazzi, A Buda, M Belfiglio, M Valentini, S Cascinu, ... Annals of Oncology 11 (7), 837-843, 2000 | 558 | 2000 |
| Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆ F Lordick, F Carneiro, S Cascinu, T Fleitas, K Haustermans, G Piessen, ... Annals of Oncology 33 (10), 1005-1020, 2022 | 551 | 2022 |
| Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non … TJ Price, M Peeters, TW Kim, J Li, S Cascinu, P Ruff, AS Suresh, ... The Lancet Oncology 15 (6), 569-579, 2014 | 529 | 2014 |
| PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer F Loupakis, L Pollina, I Stasi, A Ruzzo, M Scartozzi, D Santini, G Masi, ... Journal of clinical oncology 27 (16), 2622-2629, 2009 | 508 | 2009 |
| Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial E Van Cutsem, M Nowacki, I Lang, S Cascinu, I Shchepotin, J Maurel, ... Journal of Clinical Oncology 25 (18_suppl), 4000-4000, 2007 | 497 | 2007 |
| Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial S Cascinu, V Catalano, L Cordella, R Labianca, P Giordani, AM Baldelli, ... Journal of Clinical Oncology 20 (16), 3478-3483, 2002 | 482 | 2002 |
| PD-1 blockade therapy in renal cell carcinoma: current studies and future promises F Massari, M Santoni, C Ciccarese, D Santini, S Alfieri, G Martignoni, ... Cancer treatment reviews 41 (2), 114-121, 2015 | 460 | 2015 |
| Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study) C Pinto, F Di Fabio, S Siena, S Cascinu, FLR Llimpe, C Ceccarelli, V Mutri, ... Annals of Oncology 18 (3), 510-517, 2007 | 410 | 2007 |
| Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab A Sartore-Bianchi, M Moroni, S Veronese, C Carnaghi, E Bajetta, G Luppi, ... Journal of Clinical Oncology 25 (22), 3238-3245, 2007 | 400 | 2007 |
| Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab M Scartozzi, E Galizia, S Chiorrini, R Giampieri, R Berardi, C Pierantoni, ... Annals of oncology 20 (2), 227-230, 2009 | 390 | 2009 |
| Reviews of evidence regarding interventions to reduce tobacco use and exposure to environmental tobacco smoke DP Hopkins, PA Briss, CJ Ricard, CG Husten, VG Carande-Kulis, ... American journal of preventive medicine 20 (2), 16-66, 2001 | 335 | 2001 |
| Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with … M Scartozzi, I Bearzi, R Berardi, A Mandolesi, G Fabris, S Cascinu Journal of clinical oncology 22 (23), 4772-4778, 2004 | 331 | 2004 |
| Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer S Cascinu, MP Staccioli, G Gasparini, P Giordani, V Catalano, R Ghiselli, ... Clinical Cancer Research 6 (7), 2803-2807, 2000 | 303 | 2000 |
| The evolving role of microsatellite instability in colorectal cancer: a review F Gelsomino, M Barbolini, A Spallanzani, G Pugliese, S Cascinu Cancer treatment reviews 51, 19-26, 2016 | 291 | 2016 |
| Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. S Cascinu, L Cordella, E Del Ferro, M Fronzoni, G Catalano Journal of Clinical Oncology 13 (1), 26-32, 1995 | 260 | 1995 |
| Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up A Oaknin, TJ Bosse, CL Creutzberg, G Giornelli, P Harter, F Joly, ... Annals of oncology 33 (9), 860-877, 2022 | 244 | 2022 |
| Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. S Cascinu, A Fedeli, E Del Ferro, S Luzi Fedeli, G Catalano Journal of clinical oncology 12 (5), 1058-1062, 1994 | 241 | 1994 |
